GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » ROIC %

Humacyte (Humacyte) ROIC % : -207.57% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Humacyte ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Humacyte's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was -207.57%.

As of today (2024-05-29), Humacyte's WACC % is 10.92%. Humacyte's ROIC % is -181.86% (calculated using TTM income statement data). Humacyte earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Humacyte ROIC % Historical Data

The historical data trend for Humacyte's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte ROIC % Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROIC %
-91.48 -121.25 -131.61 -164.31

Humacyte Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -136.02 -156.37 -182.28 -195.38 -207.57

Competitive Comparison of Humacyte's ROIC %

For the Biotechnology subindustry, Humacyte's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's ROIC % distribution charts can be found below:

* The bar in red indicates where Humacyte's ROIC % falls into.



Humacyte ROIC % Calculation

Humacyte's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-96.94 * ( 1 - 0% )/( (65.198 + 52.796)/ 2 )
=-96.94/58.997
=-164.31 %

where

Humacyte's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-106.312 * ( 1 - 0% )/( (52.796 + 49.639)/ 2 )
=-106.312/51.2175
=-207.57 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Humacyte  (NAS:HUMA) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Humacyte's WACC % is 10.92%. Humacyte's ROIC % is -181.86% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Humacyte ROIC % Related Terms

Thank you for viewing the detailed overview of Humacyte's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte (Humacyte) Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente officer: Chief Regulatory Officer 90 DAVIS STREET, SEEKONK MA 02771
Todd Pope director C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713

Humacyte (Humacyte) Headlines

From GuruFocus